Latest & greatest articles for rosuvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rosuvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rosuvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rosuvastatin

1. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial

Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial To evaluate the efficacy and safety of a fixed-dose combination (FDC) of gemigliptin and rosuvastatin in patients with type 2 diabetes and dyslipidaemia.A total of 33 hospitals in Korea participated in this randomized, double-blind trial (...) of diabetic patients with dyslipidaemia. A total of 290 participants were randomly assigned at a 1:1:1 ratio to receive an FDC of gemigliptin (50 mg) and rosuvastatin (20 mg) (GEMI/ROSU FDC group), gemigliptin (50 mg) (GEMI group) or rosuvastatin (20 mg) (ROSU group). Rosuvastatin was up-titrated from 5 to 20 mg/d throughout the study period. Primary efficacy measures were changes in HbA1c and LDL-C from baseline to Week 24 between the GEMI/ROSU FDC and ROSU groups and between the GEMI/ROSU FDC and GEMI

Full Text available with Trip Pro

2018 EvidenceUpdates

2. Rosuvastatin

Rosuvastatin Top results for rosuvastatin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for rosuvastatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations

Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations Homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and accelerated atherosclerotic cardiovascular disease. Statin treatment starts at diagnosis, but no statin has been formally evaluated in, or approved for, HoFH children.The authors sought to assess (...) the LDL-C efficacy of rosuvastatin versus placebo in HoFH children, and the relationship with underlying genetic mutations.This was a randomized, double-blind, 12-week, crossover study of rosuvastatin 20 mg versus placebo, followed by 12 weeks of open-label rosuvastatin. Patients discontinued all lipid-lowering treatment except ezetimibe and/or apheresis. Clinical and laboratory assessments were performed every 6 weeks. The relationship between LDL-C response and genetic mutations was assessed

2017 EvidenceUpdates

4. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. (PubMed)

Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. Statins decrease levels of low-density lipoprotein (LDL) and triglycerides as well as cardiovascular events but increase the risk for a diagnosis of type 2 diabetes mellitus (T2DM). The risk factors associated with incident T2DM are incompletely characterized.To investigate the association of lipoprotein subclasses and size and a novel (...) levels less than 500 mg/dL. Those with T2DM were excluded. A prespecified secondary aim was to assess the effect of rosuvastatin calcium on T2DM. Incident T2DM was monitored for a median of 2.0 years. Data were collected from February 4, 2003, to August 20, 2008, and analyzed (intention-to-treat) from December 1, 2013, to January 21, 2016.Rosuvastatin calcium, 20 mg/d, or placebo.Size and concentration of lipids, apolipoproteins, and lipoproteins at baseline (11 918 patients with evaluable plasma

Full Text available with Trip Pro

2016 JAMA cardiology

5. Perioperative Rosuvastatin in Cardiac Surgery. (PubMed)

Perioperative Rosuvastatin in Cardiac Surgery. Complications after cardiac surgery are common and lead to substantial increases in morbidity and mortality. Meta-analyses of small randomized trials have suggested that perioperative statin therapy can prevent some of these complications.We randomly assigned 1922 patients in sinus rhythm who were scheduled for elective cardiac surgery to receive perioperative rosuvastatin (at a dose of 20 mg daily) or placebo. The primary outcomes were (...) surgery were lower in patients assigned to rosuvastatin than in those assigned to placebo (P<0.001). However, the rate of postoperative atrial fibrillation did not differ significantly between the rosuvastatin group and the placebo group (21.1% and 20.5%, respectively; odds ratio 1.04; 95% confidence interval [CI], 0.84 to 1.30; P=0.72), nor did the area under the troponin I-release curve (102 ng×hour per milliliter and 100 ng×hour per milliliter, respectively; between-group difference, 1%; 95% CI, -9

2016 NEJM

6. The Effect of High Dose Cilostazol and Rosuvastatin on Periprocedural Myocardial Injury in Patients with Elective Percutaneous Coronary Intervention. (PubMed)

The Effect of High Dose Cilostazol and Rosuvastatin on Periprocedural Myocardial Injury in Patients with Elective Percutaneous Coronary Intervention. The aim of our study was to assess the effect of pretreatment with cilostazol and rosuvastatin combination before elective percutaneous coronary intervention (PCI) on peri-procedural myocardial injury (PPMIJ).We randomly assigned 172 patients with stable angina pectoris scheduled for elective PCI to pre- treatment with Cilostazol 200mg (...) and Rosuvastatin 40 mg (group 1), or to pretreatment with Rosuvastatin 40 mg group (group 2). The primary end-point was the occurrence of PPMIJ defined as any cardiac troponin I (Tn I) level elevated above the upper normal limit (UNL). The occurrence of peri-procedural myocardial infarction (PPMIN) was defined as a post-procedural increase in cTnI level ≥ 5 times above the UNL.There was no significant difference in baseline characteristics between group 1 (n = 86) and group 2 (n = 86). The rate of PPMIJ (21

2016 Zhonghua Minguo xin zang xue hui za zhi = Acta Cardiologica Sinica

7. Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates Article Text Therapeutics/Prevention Randomised controlled trial In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates Michael LeFevre Statistics from Altmetric.com Commentary on: Lonn EM , Bosch J , López

2016 Evidence-Based Medicine (Requires free registration)

8. Impact of Rosuvastatin on Contrast-Induced Acute Kidney Injury in Patients at High Risk for Nephropathy Undergoing Elective Angiography (PubMed)

Impact of Rosuvastatin on Contrast-Induced Acute Kidney Injury in Patients at High Risk for Nephropathy Undergoing Elective Angiography Although statins have been shown to prevent contrast-induced acute kidney injury in patients with acute coronary syndromes, the benefit of statins is not known for patients at high risk for nephropathy who undergo elective coronary angiography. Two hundred twenty consecutive statin-naive patients with chronic kidney disease (estimated glomerular filtration rate (...) <60 ml/min/1.73 m(2)) who underwent elective coronary or peripheral angiography were randomly assigned to receive rosuvastatin (40 mg on admission, followed by 20 mg/day; n = 110) or no statin treatment (control group, n = 110). Contrast-induced acute kidney injury was defined by an absolute increase in serum creatinine of ≥0.5 mg/dl or a relative increase of ≥25% measured 48 or 72 hours after the procedure. Contrast-induced acute kidney injury occurred in 15 patients (7.2%), 9 (8.5

2015 EvidenceUpdates

9. Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome

Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2015 PedsCCM Evidence-Based Journal Club

10. Loading Dose of Rosuvastatin Before PCI and its Beneficial Post-Procedural Effects: A Systematic Review

Loading Dose of Rosuvastatin Before PCI and its Beneficial Post-Procedural Effects: A Systematic Review "Loading Dose of Rosuvastatin Before PCI and its Beneficial Post-Proced" by Andrew Ravella Galli < > > > > > Title Author Date of Graduation Summer 8-9-2014 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte MD Rights . Abstract Background: Many patients with acute coronary syndrome in the United States electively choose (...) of rosuvastatin before percutaneous coronary intervention (PCI) improve mid and long term outcomes? Methods: An exhaustive search of available medical literature was conducted using Medline-OVID, EBSCO, CINAHL, Health Source-Consumer, and Web of Science using the keywords: rosuvastatin and percutaneous coronary intervention. Relevant articles were assessed for quality using GRADE. Results: Three studies, with one including a 12-month follow up study met inclusion criteria. A prospective randomized trial

2014 Pacific University EBM Capstone Project

11. Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome. (PubMed)

Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome. In the acute respiratory distress syndrome (ARDS), inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis. We hypothesized that rosuvastatin therapy would improve clinical outcomes (...) in critically ill patients with sepsis-associated ARDS.We conducted a multicenter trial in which patients with sepsis-associated ARDS were randomly assigned to receive either enteral rosuvastatin or placebo in a double-blind manner. The primary outcome was mortality before hospital discharge home or until study day 60 if the patient was still in a health care facility. Secondary outcomes included the number of ventilator-free days (days that patients were alive and breathing spontaneously) to day 28

Full Text available with Trip Pro

2014 NEJM

12. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events Gandhi SK, Jensen MM, Fox KM, Smolen L (...) concluded that rosuvastatin was cost-effective, over a lifetime, compared with generic simvastatin or atorvastatin. The lack of detailed reporting and the highlighted limitations to this study mean that the authors’ conclusions should be considered with caution. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective This study evaluated the long-term cost-effectiveness of alternative statin therapies in Swedish patients with a high risk of cardiovascular events

Full Text available with Trip Pro

2012 NHS Economic Evaluation Database.

13. Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial

Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial Cost-effectiveness of rosuvastatin 20mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial Ohsfeldt RL, Olsson AG, Jensen MM (...) , Gandhi SK, Paulsson T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined cost-effectiveness of rosuvastatin for primary prevention of major cardiovascular disease for various risk levels. The authors concluded that primary

2012 NHS Economic Evaluation Database.

14. Effects of Rosuvastatin on Progression of Stenosis in Adult Patients With Congenital Aortic Stenosis (PROCAS Trial). (PubMed)

Effects of Rosuvastatin on Progression of Stenosis in Adult Patients With Congenital Aortic Stenosis (PROCAS Trial). Recent trials have failed to show that statin therapy halts the progression of calcific aortic stenosis (AS). We hypothesized that statin therapy in younger patients with congenital AS would be more beneficial, because the valve is less calcified. In the present double-blind, placebo-controlled trial, 63 patients with congenital AS (age 18 to 45 years) were randomly assigned (...) to receive either 10 mg of rosuvastatin daily (n = 30) or matched placebo (n = 33). The primary end point was the progression of peak aortic valve velocity. The secondary end points were temporal changes in the left ventricular mass, ascending aortic diameter, and N-terminal pro-brain natriuretic peptide (NT-proBNP). The median follow-up was 2.4 years (interquartile range 1.9 to 3.0). The mean increase in peak velocity was 0.05 ± 0.21 m/s annually in the rosuvastatin group and 0.09 ± 0.24 m/s annually

2011 EvidenceUpdates

15. Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness

Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Evidence suggests that rosuvastatin has the most potent per milligram LDL lowering effect but with appropriate dosage adjustments different statins can provide equivalent LDL reductions. Data suggests

2011 Health Technology Assessment (HTA) Database.

16. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels

The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels Choudhry NK, Patrick AR, Glynn RJ, Avorn J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rosuvastatin for apparently healthy men over 50 years old and women over 60 years old, with elevated high-sensitivity C-reactive protein levels (2mg/L or more), but normal low-density lipoprotein cholesterol levels (less than

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

17. Rosuvastatin(Crestor)

Rosuvastatin(Crestor) 2011. DAR No 4. Rosuvastatin (Crestor®) - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 4. Rosuvastatin (Crestor®) DAR No 4. Rosuvastatin (Crestor®) Content tools Share it Another statin! Expensive, potent and doubts on safety Rosuvastatin is the seventh commercialized statin in Spain. Its capacity to lower cholesterol levels is similar to other statins at equivalent doses. No advantage has been shown compared

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

18. Rosuvastatin and the JUPITER trial. A critical appraisal

Rosuvastatin and the JUPITER trial. A critical appraisal Volumen 18. DTB: Vol 18, No 5. November - December 2010 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 18, No 5. November - December 2010 DTB: Vol 18, No 5. November - December 2010 Content tools Share it Rosuvastatin and the JUPITER trial. A critical appraisal The role of hs-CRP in the pathogenesis of atherosclerosis still remains unclear. It should not be used

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

19. Rosuvastatin (Crestor®)

Rosuvastatin (Crestor®) Rosuvastatin (Crestor®) Rosuvastatin (Crestor®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Rosuvastatin (Crestor®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 1311. 2011 Authors' conclusions Rosuvastatin (Crestor®) is not recommended for use within NHS Wales for the prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors. The clinical and cost effectiveness evidence provided was not sufficient for AWMSG to recommend its use. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2011 Health Technology Assessment (HTA) Database.

20. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets (PubMed)

Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets The aim of this study was to compare ezetimibe/simvastatin combination therapy with intensified statin monotherapy as alternative treatment strategies to achieve the Joint British Societies (JBS)-2 and National Institute for Health and Clinical Excellence low-density (...) (and < 4.2 mmol/l) at screening and after a further 6-week run-in period on simvastatin 40 mg were randomised to ezetimibe/simvastatin 10/40 mg (as a combination tablet; n = 261), atorvastatin 40 mg (n = 263) or rosuvastatin 5 mg (n = 73) or 10 mg (n = 189) once daily for 6 weeks. Rosuvastatin dose was based on UK prescribing instructions. The primary outcome measure was the proportion of patients achieving LDL-C < 2 mmol/l at the end of the study.The percentage of patients (adjusted for baseline

Full Text available with Trip Pro

2010 EvidenceUpdates